Last updated 2026-07-20
Total raised
—
Last: Undisclosed Round 2018-01
Stage
Seed
Founded
2017
Headcount
21
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences
About
Aummune is a clinical-stage company developing a first-of-its-kind approach for individualized treatment of solid tumors. Their proprietary platform utilizes an efficacy-driven selection process to match and produce a patient-specific tri-functional oligonucleotide drug that safely and synergistically induces cancer cell death and activates both innate and adaptive immune responses. The company's vision is to transform life-threatening diseases into treatable conditions by designing truly individualized therapeutics that can specifically target each patient's disease-causing agent at every stage of the disease, including cancer, antibiotic-resistant bacteria, and viruses.
Headcount over time
21 employees (2026-09) · 1 point
Offices
Tel Aviv-Yafo, Israel · HQ / main office
Q&A
- What is Aummune's primary focus?
- Aummune is a clinical-stage company developing an individualized treatment approach for solid tumors, utilizing a proprietary platform to produce patient-specific tri-functional oligonucleotide drugs.
- What is the status of Aummune's lead program?
- Aummune's lead program, AM003, has initiated its Phase 1 clinical trial and is actively recruiting patients with locally advanced and metastatic solid tumors.
- When was Aummune founded?
- Aummune was founded in July 2017.
- Who are the co-founders of Aummune?
- Aummune was co-founded by Guy Neev, who also serves as CEO, and Marius Nacht.
- Which sector does Aummune primarily operate in?
- Aummune's primary sector is Health Tech & Life Sciences, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development.
- Has Aummune secured any funding?
- Aummune received funding in January 2018 from aMoon Fund.
- What is Aummune's current product stage?
- Aummune's product is currently in the clinical trial stage.
Team · 6
Fredric Price
Chairman
Barry Labinger
CEO
Irit Carmi-Levy
General Manager and Chief Scientific Officer
Karen Smith
Director and interim CMO
Michael Shenhav
Director
Yaron
Director
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
immunotherapycancerprecision-medicinehealthcare-providersclinicspersonalized-medicinetreatmentspharmaceuticalscancer-therapy
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | aummune.com |
|---|---|
| linkedin.com/company/79060359 |
Identifiers & details
| Legal name | Aummune Therapeutics Ltd. |
|---|---|
| Founded | 2017-7 |
| Employees (exact) | 21 |
Radar intelligence
Patents
| EPO | 4 |
|---|
Publications (Crossref)
| Works | 5 |
|---|
Web history (Wayback)
| Domain | aummune.com |
|---|
Certificate / subdomain footprint
| Subdomains | 3 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515674646 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2017-07-03 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 6 — people (2), annual_report (1), other (1), shares_capital (2) |
| Registered address | המצביאים 55 תל אביב - יפו |
Recent registry events
| Date | Event |
|---|---|
| 2025-10-28 | עדכון דירקטורים-הוספת דירקטור |
| 2025-10-28 | עדכון דירקטורים-הסרת דירקטור |
| 2026-05-20 | דו~ח שנתי |
| 2026-01-08 | עדכון כתובת ו/או מען דיגיטלי |
| 2025-07-07 | הקצאת מניות |
| 2025-07-07 | העברת מניות |